• The facility was inaugurated by Shri. Arjunsinh Chauhan, Hon’able Minister for Rural Housing & Development
• The Uteshiya facility, licensed by Healthium, will exclusively manufacture Healthium’s arthroscopy portfolio, including patented products in India and U.S.
• The implants and equipment help in treating soft tissue problems especially in the shoulders and knees including meniscal repairs, ACL reconstruction, ligament reconstruction and repair

Healthium Medtech Limited (“Company” or “Healthium Medtech”), a global medical devices company focused on surgical, post-surgical and chronic care, today announced the launch of its latest manufacturing facility in Ahmedabad. The facility owned by Uteshiya Medicare, is located at the Rohisa Industrial Estate, and has been licenced by Healthium Medtech to exclusively manufacture its wide range of Arthroscopy products marketed under the brand “Sironix”.   The CDSCO certified facility is spread across 70,000 sq ft.

Healthium Medtech is India’s largestl devices company independent medica and second-largest company overall, in the surgical consumables market , the  largest non-captive surgical needles manufacturer globally, by volume and the third-largest company overall in the urology collection devices market in the U.K as of fiscal 2021 .As on 31st March, 2021, one in five surgeries conducted globally, uses a Healthium product.

Healthium Medtech currently operates across eight integrated and scaled manufacturing facilities, several of which have global accreditations and registrations including US FDA, CE, ISO and TGA .Of these, seven are located in India spread across Karnataka, Uttar Pradesh, Andhra Pradesh, Tamil Nadu, Maharashtra and now Gujarat, and one in China. Healthium was the 1^st Class III medical device company in India to receive a US FDA registration for one of its facilities. The Ahmedabad facility was inaugurated by Shri. Arjunsinh Chauhan, Hon’able Minister for Rural Housing & Development.

Mr. Anish Bafna, Chief Executive Officer and Managing Director, Healthium Medtech said, “It is with great pleasure that we announce the launch of our 7^th manufacturing facility in India, at Ahmedabad. It is our endeavour to create high quality precision- based products, made in India through integrated scaled manufacturing. Arthroscopy is one of the fastest growing orthopaedic procedures in India, accounting for 15-17% of the overall procedures. We have created a patented portfolio of arthroscopy products at Healthium and we are very happy to have found in Uteshiya Medicare, a partner that offers the right environment to boost the manufacturing of our arthroscopy portfolio, while ensuring seamless delivery. I am confident that our broad-based expertise and strategic collaboration with Uteshiya , will help us make an impact in the lives of many.”

Mr. Jignesh Uteshiya, Director Uteshiya Medicare, said, “We are excited to have partnered with Healthium Medtech and look forward to manufacturing their patented arthroscopy portfolio in a completely green facility built using recycled materials, with built-in energy efficient systems, rainwater harvesting and onsite renewable energy generation. We are also optimizing and customizing operations for maximum efficiency with stringent quality control processes in place. Our most important capital is the perfect synergy of a green environment, competent talent and the effective use of global know-how through practical application.”

Arthroscopy products are used to help treat various knee and shoulder conditions such as anterior cruciate ligament reconstruction, posterior cruciate ligament injuries and other ligament reconstruction and repair and meniscal repair.

As per Frost & Sullivan report, the Indian arthroscopy devices market was valued at US$ 18.9 million in 2020, and estimated to reach US$ 47.1 million by 2025, implying a CAGR (2021-2025) of 18.6%.

Arthroscopy accounts for 15-17% of total orthopaedic procedures carried out in India, and is one of the fastest growing orthopaedic procedures. The volume of arthroscopy procedures conducted, is likely to triple in the next 5-6 years. Key drivers for growth of procedures include a growing base of arthroscopy centres and practicing specialists.

About Healthium Medtech Limited:

Healthium Medtech Limited (“Company” or “Healthium Medtech”) is a global medtech company focused on products used in surgical, post-surgical and chronic care. One in five surgeries conducted globally uses a Healthium Medtech product as of 31^st March, 2021. As of fiscal 2021, it is India’s largest independent medical device company and second-largest company overall, in the surgical consumables market. In the non-captive surgical needles segment, Healthium Medtech is the largest manufacturer globally, by volume as of March 31, 2021. Healthium Medtech is the third-largest company overall in urology collection devices market in the U.K as of fiscal 2021. With a vision to provide access to precision medtech for every patient, globally, the Company has created extensive market access in India covering over 40,000 surgeons across 18,000 hospitals, reaching 90% of all districts in India, which have secondary healthcare facilities. It also is present across 80 countries.

The Company’s diverse portfolio includes 52,000 SKUs across Advanced surgery, Urology, Arthroscopy and wound care products. With a strong focus on R & D, the company has 8 high precision, integrated and scaled manufacturing facilities with global certifications and approvals like US FDA, C.E, CDSCO, TGA and ISO. Since fiscal 2018, the company has sold 30 new products including a patented portfolio of arthroscopy products. As on July 31, 2021, the Company had a total of 21 patents in India and 11 patents in United States, and a further 22 and 6 patent applications pending approval in India and US, respectively. In addition, it has acquired 3 businesses in the last few months to expand market reach and its product portfolio.

“Disclaimer: Healthium Medtech Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its equity shares and has filed a draft red herring prospectus (“DRHP”) with the Securities and Exchange Board of India. The DRHP is available on the website of the SEBI at www.sebi.gov.in as well as on the websites of the book running lead managers, ICICI Securities Limited, CLSA India Private Limited, Credit Suisse Securities (India) Private Limited and Nomura Financial Advisory and Securities (India) Private Limited, at www.icicisecurities.com, www.india.clsa.com, www.credit-suisse.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively, and the websites of the stock exchange(s) at www.bseindia.com and www.nseindia.com, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see “Risk Factors” of the RHP / Prospectus, when available. Potential investors should not rely on the DRHP for any investment decision.”